Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2017

View Archived Issues

Ipsen to acquire five consumer healthcare products from Sanofi in Europe

Aeterna Zentaris plans to pursue FDA registration of Macrilen following review of phase III data

Modulators of serotonin signaling show promise for Dravet syndrome therapy

Inovio enters agreement with ApolloBio regarding VGX-3100

Zogenix provides update on phase III study of ZX-008 in Dravet syndrome

Anti-VEGF-B agent CSL-346 developed to treat diabetic kidney disease

M-207 meets both coprimary endpoints in the ZOTRIP pivotal efficacy trial in migraine

Eicosanoid analogues patented by the University of Texas System, OMEICOS, and Max Delbrueck Center

Phase IIb study of Aviragen's vapendavir misses primary endpoint

miRagen Therapeutics and Signal Genetics complete merger

Axovant Sciences reports interim results from phase II study of nelotanserin in Lewy body dementia

Vifor Pharma and ChemoCentryx expand avacopan agreement

European Commission approves Olumiant for rheumatoid arthritis

MVT-5873 plus PEGPH-20 shows promising results in animal model of pancreatic cancer

Voyager Therapeutics selects clinical candidate for ALS

Ritter Pharmaceuticals and UBC collaborate to study role of microbiome in environmental enteropathy

Mitochondrial dysfunction due to PINK1 gene mutation may be circumvented in Parkinson's disease

Marathon pauses commercialization efforts for Emflaza

IP-10, a promising biomarker for TAFRO syndrome